PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1885121

[Paroxysmal choreoathetosis].

S Fegers
View original source ↗Export metadata ↓

Abstract

Paroxysmal Choreoathetosis (PC) is a rare disorder which is characterized by spells of involuntary movements of the limbs, the head and the trunk lasting from a minute to several hours. PC is classified in two main types. In Paroxysmal Dystonic Choreoathetosis (PDC) the attacks are prolonged and precipitated by alcohol, emotion or fatigue, in Paroxysmal Kinesigenic Choreoathetosis (PKC) the attacks last less than 5 minutes and are precipitated by sudden movements. Although the pathophysiology of the disorder ist still uncertain, it is supposed to be an extrapyramidal disorder. Clinical features, therapeutical and differential diagnostic aspects are discussed. There is a certain risk that the disorder is misinterpreted as psychogenic or hysterical in nature. The mostly good response to medication can help the patients avoid superimposed emotional problems.

Explore related subjects

AnticonvulsantsAthetosisBrainChoreaElectroencephalographyHumansNeurologic ExaminationPsychotropic DrugsEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Fegers. 1991. [Paroxysmal choreoathetosis].. https://doi.org/10.1055/s-2007-1000699

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗